Early trial tests promising new combo for Tough-to-Treat lung cancer
NCT ID NCT04612751
Summary
This early-stage study is testing the safety of a new drug called datopotamab deruxtecan when combined with immunotherapy, with or without a standard chemotherapy drug, for people with advanced non-small cell lung cancer. The main goal is to find safe dose levels and see how well the body tolerates these combinations. Researchers will also check if the treatment shows any early signs of helping to control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
La Jolla, California, 92093, United States
-
Research Site
Santa Ana, California, 92705, United States
-
Research Site
St Louis, Missouri, 63110, United States
-
Research Site
Hackensack, New Jersey, 07601, United States
-
Research Site
Cleveland, Ohio, 44106, United States
-
Research Site
Philadelphia, Pennsylvania, 19111, United States
-
Research Site
Dallas, Texas, 75230, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
San Antonio, Texas, 78229, United States
-
Research Site
Fairfax, Virginia, 22031, United States
-
Research Site
Hasselt, 3500, Belgium
-
Research Site
Roeselare, 8800, Belgium
-
Research Site
Aviano, 33081, Italy
-
Research Site
Meldola, 47014, Italy
-
Research Site
Orbassano, 10043, Italy
-
Research Site
Roma, 00144, Italy
-
Research Site
Kōtoku, 135-8550, Japan
-
Research Site
Sunto-gun, 411-8777, Japan
-
Research Site
Yokohama, 241-8515, Japan
-
Research Site
Gdansk, 80-952, Poland
-
Research Site
Lodz, 93-338, Poland
-
Research Site
Lublin, 20-090, Poland
-
Research Site
Warsaw, 02-781, Poland
-
Research Site
A Coruña, 15005, Spain
-
Research Site
Badalona, 08916, Spain
-
Research Site
Barcelona, 8036, Spain
-
Research Site
Madrid, 28034, Spain
-
Research Site
Madrid, 28046, Spain
-
Research Site
Madrid, 28050, Spain
-
Research Site
Seville, 41015, Spain
-
Research Site
Hsinchu, 300, Taiwan
-
Research Site
Taichung, 40705, Taiwan
-
Research Site
Tainan, 704, Taiwan
-
Research Site
Taipei, 100, Taiwan
-
Research Site
Taipei, 110, Taiwan
-
Research Site
Taipei, 11217, Taiwan
-
Research Site
Taoyuan District, 00333, Taiwan
-
Research Site
Adana, 01060, Turkey (Türkiye)
-
Research Site
Ankara, 06800, Turkey (Türkiye)
-
Research Site
Ankara, 6200, Turkey (Türkiye)
-
Research Site
Istanbul, 34010, Turkey (Türkiye)
-
Research Site
Izmir, 35330, Turkey (Türkiye)
Conditions
Explore the condition pages connected to this study.